Long COVID

Long COVID or long-haul COVID is a group of health problems persisting or developing after an initial period of COVID 19 from SARS-CoV-2 infection.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 13 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Long COVID or long-haul COVID is a group of health problems persisting or developing after an initial period of COVID 19 from SARS-CoV-2 infection. Symptoms can last weeks, months, or years and are often debilitating.

The World Health Organization defines long COVID as starting three months after the initial disease, but other agencies define it as starting at four weeks after the initial COVID-19. Long COVID is characterised by a large number of symptoms that sometimes disappear and then reappear.

Commonly reported symptoms of long COVID are fatigue, memory problems, shortness of breath, and sleep disorder. Several other symptoms, including headaches, mental health issues, initial loss of smell or taste, muscle weakness, fever, and cognitive dysfunction ("brain fog") may also present.

Symptoms often get worse after mental or physical effort, a process called post-exertional malaise (PEM). There is a large overlap in symptoms with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The causes of long COVID are not understood.

Hypotheses include lasting damage to organs and blood vessels, problems with blood clotting, neurological dysfunction, persistent virus or a reactivation of latent viruses and autoimmunity. Diagnosis of long COVID is based on (suspected or confirmed) COVID 19 infection or symptoms and by excluding alternative diagnoses.…

Long COVID or long-haul COVID is a group of health problems persisting or developing after an initial period of COVID 19 from SARS-CoV-2 infection. Symptoms can last weeks, months, or years and are often debilitating.

The World Health Organization defines long COVID as starting three months after the initial disease, but other agencies define it as starting at four weeks after the initial COVID-19. Long COVID is characterised by a large number of symptoms that sometimes disappear and then reappear.

Commonly reported symptoms of long COVID are fatigue, memory problems, shortness of breath, and sleep disorder. Several other symptoms, including headaches, mental health issues, initial loss of smell or taste, muscle weakness, fever, and cognitive dysfunction ("brain fog") may also present.

Symptoms often get worse after mental or physical effort, a process called post-exertional malaise (PEM). There is a large overlap in symptoms with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The causes of long COVID are not understood.

Hypotheses include lasting damage to organs and blood vessels, problems with blood clotting, neurological dysfunction, persistent virus or a reactivation of latent viruses and autoimmunity. Diagnosis of long COVID is based on (suspected or confirmed) COVID 19 infection or symptoms and by excluding alternative diagnoses.

Many of the symptoms attributed to long COVID are non-specific and occur in other conditions, which makes it difficult to know the true prevalence of long COVID. As of 2025, the prevalence of long COVID is estimated to be about 6–7% in adults, and about 1% in children. Prevalence might be reduced after vaccination.

Risk factors include but are not limited to higher age, female sex, having asthma, and a more severe initial COVID 19 infection. Anyone can develop long COVID. , there are no validated effective treatments. Management of long COVID depends on symptoms.

Rest is recommended for fatigue and pacing for post-exertional malaise. People with severe symptoms or those who were in intensive care may require care from a team of specialists. Most people with symptoms at 4 weeks recover by 12 weeks.

Recovery is slower (or plateaus) for those still ill at 12 weeks. For a subset of people, for instance, those meeting the criteria for ME/CFS, symptoms may be lifelong. Globally, over 400 million people have experienced long COVID.

Long COVID may be responsible for a loss of 1% of the world's gross domestic product.

Signs and symptoms

There is a large set of symptoms associated with long COVID, impacting many different organs and body systems. Long COVID symptoms can differ significantly from person to person. Symptom severity ranges from mild to incapacitating.

Many symptoms reported in long COVID are non-specific, which makes it difficult to definitively attribute them to prior SARS-CoV-2 infection. Common symptoms reported in studies include fatigue, muscle pain, shortness of breath, chest pain, cognitive dysfunction ("brain fog") and post-exertional malaise (symptoms worsen after activity).

This symptom worsening typically occurs 12 to 48 hours after activity and can be triggered by either mental or physical effort. It lasts between days and weeks. Children and adolescents can also experience serious symptoms and long-term adverse health effects, including serious mental health impacts related to persistent COVID 19 symptoms.

The most common symptoms in children are persistent fever, sore throat, problems with sleep, headaches, shortness of breath, muscle weakness, fatigue, loss of smell or distorted smell, and anxiety. Children and adolescents with long COVID experience three or more symptoms more frequently than control groups, but this has low certainty.

Risk factors

Women are more at risk than men. Age has been identified as another risk factor, with older people seemingly more at risk. This is also true for children, with older children at a higher risk than younger children.

Most diagnoses of long COVID are in the 36–50 age bracket. Risks of developing long COVID are also higher for people with lower incomes, people with fewer years of education and those from disadvantaged ethnic groups. People who smoke also have a higher risk of developing long COVID.

Various health issues raise the risk of long COVID. For instance, people with obesity more often report long COVID. Asthma and chronic obstructive pulmonary disease are also risk factors.

In terms of mental health, depression and anxiety raise risks. Characteristics of the acute infection play a role in developing long COVID. People who experience a larger number of symptoms during the acute infection are more likely to develop long COVID, as well as people who require hospitalisation.

In children and young people, the risk factors for long COVID include female sex, older age, and pre-existing diseases or mental health problems. Long COVID risks may have been higher with the SARS-CoV2 Delta variant compared to the Omicron variant. The higher infection rate from the Omicron variant means that it is still responsible for a large group of long-haulers.

Diagnosis

There is currently no diagnostic test for long COVID, and there is no consensus on diagnostic criteria. There are no standardised tests to determine if symptoms persisting after COVID 19 infection are due to long COVID. Diagnosis is based on a history of suspected or confirmed COVID 19 symptoms, and by considering and ruling out alternative diagnoses.

Diagnosis of long COVID can be challenging because of the wide range of symptoms people with long COVID may display. Many of the symptoms are not specific to long COVID and can occur in other medical conditions.

Early diagnostic criteria of long COVID required a laboratory-confirmed COVID 19 infection, but criteria do not require this anymore, given that people may not get tested during the acute infection. For instance, people who develop long COVID after asymptomatic infection would have little reason to get tested. Furthermore, tests for COVID are not foolproof, and can come back negative.

False negatives are more common for children, women and people with a low viral load. There are diagnostic tools available for some elements of long COVID, such as the tilt table test or a NASA lean test for POTS and MRI scans to test for cardiovascular impairment. Routine tests offered in standard care often come back normal.

Prevention

Preventing a COVID-19 infection is the most effective way to prevent long COVID, for instance by wearing a properly fitted N95 mask, improving ventilation, avoiding contact with people who test positive for COVID, and washing hands. Treatment during the acute phase may also reduce the risk of long COVID.

For example, in two large, randomised, placebo-controlled clinical trials, treatment with metformin during acute infection lowered risk of diagnosis with Long COVID by 41-50%. COVID-19 vaccination seems to reduce risk of long COVID. Three doses of a COVID-19 vaccine may reduce the risk by 70%, while two doses give 43% protection and one dose gives 19% protection.

The evidence is based on observational studies, rather than on randomised clinical trials. The large randomised control trials on COVID-19 vaccines did not include long COVID as an outcome measure.

An analysis involving more than 20 million adults found that vaccinated people had a lower risk of long COVID compared with those who had not received a COVID 19 vaccine; they were also protected against blood clots and heart failure development after the infection.

Treatment

As of 2026, no treatments have been established as effective for long COVID as a whole, although treatments are available for some individual symptoms and associated conditions. A 2025 review of interventions for managing long COVID symptoms concluded that the evidence for selecting certain interventions was highly imprecise with substantial clinical uncertainty, leading affected people to use costly and ineffective self-treatment options.

Dismissive attitudes by clinicians for applying interventions, inadequate coverage of treatment by insurance companies, and restricted access to clinical specialists are also discouraging long COVID treatment plans. People with long COVID may need care within several clinical disciplines for long-term monitoring or intervention of ongoing symptoms, and to implement social services, physical therapy, or mental health care.

In some countries, such as the UK and Germany, specialised long COVID outpatient clinics have been established to assess individual cases for the extent of surveillance and treatment needed. Primary care physicians should provide the first assessment of people with long COVID symptoms, leading to specialist referrals for more complex long COVID symptoms.

Management of long COVID depends on symptoms. Rest, planning and prioritising are advised for people with fatigue. People who get post-exertional malaise may benefit from activity management with pacing.

People with allergic-type symptoms, such as skin rashes, may benefit from antihistamines. Those with autonomic dysfunction may benefit from increased intake of fluids, electrolytes and compression garments.

Long-term follow-up of people with long COVID involves outcome reports from the people themselves to assess the impact on their quality of life, especially for those who were not hospitalised and receiving regular clinical follow-up. Digital technologies, such as videoconferencing, are being implemented between primary care physicians and people with long COVID as part of long-term monitoring.

Epidemiology

Estimates of the incidence and prevalence of long COVID vary widely. The estimates depend on the definition of long COVID, the population studied, as well as a number of other methodological differences, such as whether a comparable cohort of individuals without COVID 19 were included, what kinds of symptoms are considered representative of long COVID, and whether long COVID is assessed through a review of symptoms, through self-report of long COVID status, or some other method.

A 2024 systematic umbrella review found that selection and ascertainment biases were common in the prevalence literature. In general, estimates of long COVID incidence based on statistically random sampling of the population are much lower than those based on certified infection, which has a tendency to skew towards more serious cases (including over-representation of hospitalised patients).

Further, since incidence appears to be correlated with severity of infection, it is lower in vaccinated groups, on reinfection and during the omicron era, meaning that the time when data was recorded is important. For example, the UK's Office for National Statistics reported in February 2023 (based on random sampling) that "2.4% of adults and 0.6% of children and young people reported long COVID following a second COVID 19 infection".

However, a prospective study by Statistics Canada identified a cumulative incidence of 15% after a first infection, 27% after two infections, and 38% after 3 infections. An August 2024 review found that the prevalence of long COVID is estimated to be about 6–7% in adults, and about 1% in children. By the end of 2023, roughly 400 million people had or have had long COVID.

This may be a conservative estimate, as it is based on studies counting those with specific long COVID symptoms only, and not counting those who developed long COVID after an asymptomatic infection. While hospitalised people have higher risks of getting long COVID, most long-haulers had a mild infection and were able to recover from the acute infection at home.

Two meta-analyses estimated the incidence of long COVID after infection at 43% and 58%. These estimates are controversial, as the primary studies they assessed had sampling and other biases. Furthermore, none of the definitions of long COVID have a minimum severity, so these numbers also include people with a single symptom that does not really affect them much.

In the United States in June 2023, 6% of the population indicated having long COVID, as defined as symptoms that last for 3 months or more. This percentage had stayed stable since January that year, but was a decrease compared to June 2022. Of people who had had a prior COVID infection, 11% indicated having long COVID.

A quarter of those reported significant limitation in activity. A study by the Medical Expenditure Panel Survey estimated that nearly 18 million people — had suffered from long COVID as of 2023, building on a study sponsored by the Agency for Healthcare Research and Quality.

In a large population cohort study in Scotland, 42% of respondents said they had not fully recovered after 6 to 18 months after catching COVID, and 6% indicated they had not recovered at all. The risk of long COVID was associated with disease severity; people with asymptomatic infection did not have increased risk of long COVID symptoms compared to people who had never been infected.

Those that had been hospitalised had 4.6 times higher odds of no recovery compared to nonhospitalised people. Long COVID is less common in children and adolescents than in adults. Around 16% of children and adolescents develop long COVID following infection.

General

Long-term effects of coronavirus (long COVID) at UK National Health Service

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378924261 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

29 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.